drug_type
RELEVANT_DRUG
intervention_type
Cell therapy (CAR-NK)
drug_description
Allogeneic cord blood–derived natural killer cell therapy engineered to express an anti-TROP2 chimeric antigen receptor and IL-15; CAR engagement of TROP2 triggers NK cytotoxicity while IL-15 signaling sustains survival, proliferation, and in vivo persistence.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Natural Killer Cells
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic cord blood–derived NK cells engineered to express an anti-TROP2 chimeric antigen receptor and IL-15. CAR recognition of TROP2 on tumor cells triggers NK activation and cytotoxicity (perforin/granzyme-mediated lysis and cytokine release), while IL-15 autocrine signaling sustains NK survival, proliferation, and in vivo persistence; an inducible caspase-9 safety switch allows drug-mediated ablation if needed.
drug_name
TROP2-CAR-NK Cells
nct_id_drug_ref
NCT06066424